top of page

TAX 324: Etude Posner : CTI PF vs TPF 

TAX 324 design.png
Essai TAX324 results 1.png
Essai TAX324 results 2.png

Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer

Marshall R. Posner, M.D.,  Diane M. Hershock, M.D., Ph.D.,  Cesar R. Blajman, M.D.,  Elizabeth Mickiewicz, M.D.,  Eric Winquist, M.D.,  Vera Gorbounova, M.D.,  Sergei Tjulandin, M.D.,  Dong M. Shin, M.D.,  Kevin Cullen, M.D.,  Thomas J. Ervin, M.D.,  Barbara A. Murphy, M.D.,  Luis E. Raez, M.D.,  et al., for the TAX 324 Study Group

N Engl J Med 2007; 357:1705-1715

Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, et al.

Long term results of TAX324, a randomized phase III trial of sequential therapy with TPF versus PF in locally advanced squamous cell cancer of the head and neck.

Lancet Oncol. févr 2011;12(2):153‑9.

bottom of page